Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Depreciation & Amortization - Total (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Depreciation & Amortization - Total for 6 consecutive years, with $400000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization - Total rose 300.0% to $400000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.1 million, a 120.0% increase, with the full-year FY2024 number at $600000.0, changed 0.0% from a year prior.
  • Depreciation & Amortization - Total was $400000.0 for Q3 2025 at Vivos Therapeutics, up from $300000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization - Total ranged from a high of $400000.0 in Q3 2025 to a low of $100000.0 in Q1 2021.
  • A 5-year average of $176470.6 and a median of $200000.0 in 2021 define the central range for Depreciation & Amortization - Total.
  • Peak YoY movement for Depreciation & Amortization - Total: skyrocketed 800.67% in 2021, then crashed 50.0% in 2023.
  • Vivos Therapeutics' Depreciation & Amortization - Total stood at $100000.0 in 2021, then surged by 100.0% to $200000.0 in 2022, then changed by 0.0% to $200000.0 in 2023, then changed by 0.0% to $200000.0 in 2024, then surged by 100.0% to $400000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Depreciation & Amortization - Total are $400000.0 (Q3 2025), $300000.0 (Q2 2025), and $200000.0 (Q1 2025).